The prevalence of mild cognitive impairment (MCI) and dementia is increasing globally as people live longer. Vascular dementia (VaD) and Alzheimer’s disease (AD) are the most common forms of dementia, and cerebrovascular disease (CVD) is often concomitant with AD (AD + CVD). The goal of treatment is to stabilize or slow disease progression, reduce behavioral and psychological symptoms of dementia (BPSD), improve quality of life, and reduce caregiver burden. In Asia, the first-line therapies for dementia are acetylcholinesterase inhibitors (AChEIs), N‐methyl‐D‐aspartate (NMDA) receptor antagonists (e.g., memantine) are second-line therapies, and the proprietary ginkgo (Ginkgo biloba, Ginkgoaceae) leaf extract EGb761 (Dr. Willmar Schwabe GmbH & Co. KG; Karlsruhe, Germany) is also used. In China, the Philippines, Thailand, and Vietnam, EGb 761 is classified as a drug; in Malaysia and Singapore, it is regulated as a supplement; and in Indonesia, it is classified as a “phytopharmaceutical.” To help guide clinical practice in…